Insider · CIK 0001464583
Michael R Megna
officer
Files at KNSA (Kiniksa Pharmaceuticals International, plc). First filing Dec 2, 2024, latest Sep 3, 2026.
Michael R Megna files SEC Form 4 as officer at KNSA (Kiniksa Pharmaceuticals International, plc). Since Dec 2, 2024, Michael R Megna has reported 0 open-market buys worth $0 and 8 open-market sells worth $4.6M, the latest filed on Sep 3, 2026.
A track record needs three past buys with six months of prices behind them; Michael R Megna has 0, so none is measured yet.
The newest scored trade: sold $369k of KNSA on Sep 3, 2026, filed Sep 3, 2026, scored 0 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $2.3M.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 8
$0 bought, $4.6M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KNSA: Kiniksa Pharmaceuticals International, plc
KNSAOct 9, 2026 · close 79.78
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Kiniksa Pharmaceuticals International, plc | $369k 4,600 shares | -14% | - | |
| 40Moderate | Kiniksa Pharmaceuticals International, plc | $2.0M 50,490 shares | -65% | +115% from low0% from high | |
| 16Weak | Kiniksa Pharmaceuticals International, plc | $383k 11,000 shares | -22% | +95% from low0% from high | |
| 24Weak | Kiniksa Pharmaceuticals International, plc | $550k 17,000 shares | -34% | +81% from low0% from high | |
| 22Weak | Kiniksa Pharmaceuticals International, plc | $437k 15,211 shares | -32% | +60% from low0% from high | |
| 22Weak | Kiniksa Pharmaceuticals International, plc | $471k 17,647 shares | -35% | +47% from low-4% from high | |
| 17Weak | Kiniksa Pharmaceuticals International, plc | $203k 9,051 shares | -25% | - | |
| 12Weak | Kiniksa Pharmaceuticals International, plc | $194k 8,646 shares | -25% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 3, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | 11,000 0.03% of outstanding | $383k | Sep 3, 2025 | $987k |
| Aug 4, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | 17,000 0.04% of outstanding | $550k | Aug 4, 2025 | $908k |
| Jun 3, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | 15,211 0.04% of outstanding | $437k | Jun 3, 2025 | $674k |
| May 7, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | 17,647 0.04% of outstanding | $471k | May 7, 2025 | $203k |
| Mar 12, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | 9,051 0.02% of outstanding | $203k | Mar 12, 2025 | none |
| Nov 27, 2024 | KNSA Kiniksa Pharmaceuticals International, plc | 17,697 0.04% of outstanding | $397k | Nov 27, 2024 | none |
Transactions
The newest 50 of 85 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Class A Ordinary Share10b5-1 | +279 | $33.50 | $9,347 | 27,697 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +3,932 | - | - | 31,629 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +2,558 | - | - | 34,187 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +2,362 | - | - | 36,549 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +2,644 | - | - | 39,193 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | FTax withholding Class A Ordinary Share10b5-1 | -5,531 | $79.28 | $438k | 33,662 | 40 d ago |
| Sep 3, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | SOpen-market sale Class A Ordinary Share10b5-1 | -4,600 | $80.30 | $369k | 29,062 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Restricted Share Unitderivative10b5-1 | +3,650 | $0.00 | $0 | 3,650 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Share Optionderivative10b5-1 | +14,600 | $0.00 | $0 | 14,600 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative10b5-1 | -2,644 | $0.00 | $0 | 7,931 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative10b5-1 | -2,362 | $0.00 | $0 | 4,725 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative10b5-1 | -2,558 | $0.00 | $0 | 2,557 | 40 d ago |
| Sep 1, 2026 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative10b5-1 | -3,932 | $0.00 | $0 | 0 | 40 d ago |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +791 | $15.50 | $12k | 38,892 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +6,195 | $12.97 | $80k | 45,087 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +9,831 | $11.10 | $109k | 54,918 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +9,831 | $11.97 | $118k | 64,749 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +12,787 | $10.76 | $138k | 77,536 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | SOpen-market sale Class A Ordinary Share10b5-1 | -37,255 | $38.72 | $1.4M | 40,281 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | SOpen-market sale Class A Ordinary Share10b5-1 | -13,235 | $39.31 | $520k | 27,046 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Share Optionderivative10b5-1 | -791 | $0.00 | $0 | 0 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Share Optionderivative10b5-1 | -6,195 | $0.00 | $0 | 0 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Share Optionderivative10b5-1 | -9,831 | $0.00 | $0 | 0 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Share Optionderivative10b5-1 | -9,831 | $0.00 | $0 | 0 | Oct 22, 2025 |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Share Optionderivative10b5-1 | -12,787 | $0.00 | $0 | 0 | Oct 22, 2025 |
| Oct 4, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share | +175 | - | - | 38,186 | Oct 8, 2025 |
| Oct 4, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | FTax withholding Class A Ordinary Share | -85 | $38.49 | $3,272 | 38,101 | Oct 8, 2025 |
| Oct 4, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative | -175 | $0.00 | $0 | 0 | Oct 8, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +2,363 | - | - | 35,404 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +2,557 | - | - | 37,961 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +3,933 | - | - | 41,894 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | FTax withholding Class A Ordinary Share10b5-1 | -4,282 | $33.49 | $143k | 37,612 | Sep 3, 2025 |
| Sep 2, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +774 | - | - | 38,386 | Sep 3, 2025 |
| Sep 2, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | FTax withholding Class A Ordinary Share10b5-1 | -375 | $34.28 | $13k | 38,011 | Sep 3, 2025 |
| Sep 3, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +11,000 | $17.92 | $197k | 49,011 | Sep 3, 2025 |
| Sep 3, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | SOpen-market sale Class A Ordinary Share10b5-1 | -11,000 | $34.84 | $383k | 38,011 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Restricted Share Unitderivative10b5-1 | +10,575 | $0.00 | $0 | 10,575 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Share Optionderivative10b5-1 | +21,150 | $0.00 | $0 | 21,150 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative10b5-1 | -2,363 | $0.00 | $0 | 7,087 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative10b5-1 | -2,557 | $0.00 | $0 | 5,115 | Sep 3, 2025 |
| Sep 1, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative10b5-1 | -3,933 | $0.00 | $0 | 3,932 | Sep 3, 2025 |
| Sep 2, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitderivative10b5-1 | -774 | $0.00 | $0 | 0 | Sep 3, 2025 |
| Sep 3, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Share Optionderivative10b5-1 | -11,000 | $0.00 | $0 | 0 | Sep 3, 2025 |
| Jul 15, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Class A Ordinary Share10b5-1 | +495 | $15.63 | $7,737 | 33,041 | Aug 6, 2025 |
| Aug 4, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +17,000 | $15.52 | $264k | 50,041 | Aug 6, 2025 |
| Aug 4, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | SOpen-market sale Class A Ordinary Share10b5-1 | -17,000 | $32.35 | $550k | 33,041 | Aug 6, 2025 |
| Aug 4, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Share Optionderivative10b5-1 | -17,000 | $0.00 | $0 | 0 | Aug 6, 2025 |
| Jun 3, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share10b5-1 | +15,211 | $15.50 | $236k | 47,757 | Jun 5, 2025 |
| Jun 3, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | SOpen-market sale Class A Ordinary Share10b5-1 | -15,211 | $28.75 | $437k | 32,546 | Jun 5, 2025 |
| Jun 3, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Share Optionderivative10b5-1 | -15,211 | $0.00 | $0 | 791 | Jun 5, 2025 |
50 of 85 rows shown.
Questions about Michael R Megna
Answered from the filings on this page, as of the latest one.
Is Michael R Megna buying or selling?
In the last 12 months Michael R Megna reported 0 open-market buys worth $0 and 2 open-market sells worth $2.3M on SEC Form 4; the latest was sold $369k of KNSA on Sep 3, 2026. Grants, option exercises and tax withholding are not counted.
How did Michael R Megna's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael R Megna has 0.
Where does Michael R Megna file Form 4?
Michael R Megna has filed Form 4 at KNSA (Kiniksa Pharmaceuticals International, plc) as CHIEF ACCOUNTING OFFICER. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.